Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report

Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report

There are various mechanisms underlying the resistance of EGFR-mutant lung adenocarcinoma to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). We herein report a case of pulmonary adenocarcinoma with EGFR mutation (exon 19 deletion and T790M) that acquired resistance to osimer...

Full description

Bibliographic Details
Main Authors:	Yuri Taniguchi, Hajime Horiuchi, Teppei Morikawa, Kazuhiro Usui
Format:	Article
Language:	English
Published:	Karger Publishers 2018-05-01
Series:	Case Reports in Oncology
Subjects:	Osimertinib T790M Acquired resistance Small-cell carcinoma transformation Non-small-cell carcinoma Epidermal growth factor receptor
Online Access:	https://www.karger.com/Article/FullText/489603

Similar Items

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report
by: Shinichi Miyazaki, et al.
Published: (2020-08-01)

Primary resistance to osimertinib despite acquired T790M
by: Ling‐Kai Chang, et al.
Published: (2020-03-01)

Osimertinib making a breakthrough in lung cancer targeted therapy
by: Zhang H
Published: (2016-09-01)

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
by: Mazza V, et al.
Published: (2017-07-01)

Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harboring uncommon EGFR mutations: a case report and literature review
by: Hakozaki T, et al.
Published: (2019-01-01)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
by: Qiufan Zheng, et al.
Published: (2020-02-01)

Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
by: Akira Nakao, et al.
Published: (2020-06-01)

Osimertinib in NSCLC: Real-World Data From New Zealand
by: Yeojeong Jane So, MbChB, FRACP, et al.
Published: (2020-06-01)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
by: Atsushi Osoegawa, MD, PhD, et al.
Published: (2021-07-01)

Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small cell lung carcinoma
by: Takayuki Kishikawa, et al.
Published: (2020-04-01)

Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
by: Li H, et al.
Published: (2019-09-01)

Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review
by: Toshiyuki Sumi, et al.
Published: (2021-06-01)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
by: Akihiro Yoshimura, et al.
Published: (2019-03-01)

Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival
by: Takashi Higuchi, et al.
Published: (2020-10-01)

A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)
by: Kazushige Wakuda, et al.
Published: (2020-05-01)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-08-01)

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
by: Igawa S, et al.
Published: (2019-05-01)

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors
by: K K Laktionov, et al.
Published: (2018-06-01)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
by: Svetlana V. Odintsova, et al.
Published: (2020-07-01)

Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
by: Maria Gabriela O. Fernandes, et al.
Published: (2021-05-01)

Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations
by: Weigang Xiu, et al.
Published: (2021-04-01)

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
by: Peng D, et al.
Published: (2021-02-01)

Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer
by: Zitong ZHAO, et al.
Published: (2020-04-01)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
by: Asako Matsuda, et al.
Published: (2019-12-01)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Luwei Han, et al.
Published: (2021-04-01)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
by: Marialucia Iacovino, et al.
Published: (2020-12-01)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
by: MuYun Peng, et al.
Published: (2020-09-01)

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial–mesenchymal transition
by: Kejun Liu, et al.
Published: (2021-05-01)

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
by: Lee CS, et al.
Published: (2021-08-01)

Mixed response to osimertinib and the beneficial effects of additional local therapy
by: Yuki Shinno, et al.
Published: (2019-04-01)

A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report
by: Sun Y, et al.
Published: (2020-11-01)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
by: Changhui Li, et al.
Published: (2021-05-01)

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs
by: Taira Ninomaru, et al.
Published: (2021-03-01)

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
by: Beung-Chul Ahn, et al.
Published: (2021-07-01)

Different Clinicopathologic and Computed Tomography Imaging Characteristics of Primary and Acquired EGFR T790M Mutations in Patients with Non-Small-Cell Lung Cancer
by: Hou D, et al.
Published: (2021-08-01)

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
by: Mariano Provencio, et al.
Published: (2021-03-01)

Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital
by: Venkata Pradeep Babu Koyyala, et al.
Published: (2018-01-01)

EGFR targeted therapy in lung cancer; an evolving story
by: C. Bartholomew, et al.
Published: (2017-01-01)

A “triple whammy” in adenocarcinoma lung
by: Mahismita Patro, et al.
Published: (2019-01-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)